Waldencast PLC (NASDAQ:WALD) Short Interest Down 25.7% in January

Waldencast PLC (NASDAQ:WALD) was the recipient of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totaling 596,028 shares, a decrease of 25.7% from the December 31st total of 801,939 shares. Based on an average daily trading volume, of 64,202 shares, the days-to-cover ratio is currently 9.3 days. Based on an average daily trading volume, of 64,202 shares, the days-to-cover ratio is currently 9.3 days.

Waldencast Stock Up 13.5%

WALD stock traded up $0.22 during mid-day trading on Friday, reaching $1.81. The company’s stock had a trading volume of 194,502 shares, compared to its average volume of 53,301. Waldencast has a 12 month low of $1.45 and a 12 month high of $3.63. The company has a current ratio of 1.53, a quick ratio of 0.67 and a debt-to-equity ratio of 0.32. The business’s 50 day moving average price is $1.94 and its 200 day moving average price is $1.92.

Waldencast (NASDAQ:WALD) last announced its quarterly earnings data on Monday, November 24th. The company reported ($0.69) EPS for the quarter. The firm had revenue of $66.14 million for the quarter. Research analysts expect that Waldencast will post -0.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

WALD has been the subject of a number of research analyst reports. Canaccord Genuity Group decreased their target price on Waldencast from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, November 25th. Jefferies Financial Group began coverage on shares of Waldencast in a research note on Wednesday, January 14th. They set a “buy” rating and a $2.00 price objective for the company. Telsey Advisory Group downgraded shares of Waldencast from an “outperform” rating to a “market perform” rating and set a $3.00 price objective for the company. in a research report on Tuesday, November 25th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Waldencast in a research note on Wednesday, January 21st. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Waldencast presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.42.

Institutional Trading of Waldencast

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in WALD. JPMorgan Chase & Co. boosted its holdings in Waldencast by 12.7% in the third quarter. JPMorgan Chase & Co. now owns 57,702 shares of the company’s stock worth $114,000 after acquiring an additional 6,516 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of Waldencast during the third quarter worth approximately $78,000. UBS Group AG lifted its stake in shares of Waldencast by 466.2% in the third quarter. UBS Group AG now owns 838,536 shares of the company’s stock valued at $1,660,000 after buying an additional 690,441 shares in the last quarter. Milestones Administradora de Recursos Ltda. grew its holdings in shares of Waldencast by 10.3% during the third quarter. Milestones Administradora de Recursos Ltda. now owns 2,425,677 shares of the company’s stock valued at $4,803,000 after buying an additional 225,677 shares during the last quarter. Finally, Covestor Ltd increased its position in shares of Waldencast by 98,716.0% during the third quarter. Covestor Ltd now owns 24,704 shares of the company’s stock worth $49,000 after acquiring an additional 24,679 shares in the last quarter. 41.97% of the stock is owned by institutional investors.

About Waldencast

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians. The company also offers clean makeup products under the Milk Makeup brand. It sells its products to dermatologists, plastic surgeons, and other physicians who focuses on aesthetic and therapeutic skincare, including physicians on site at medical spas, through its direct sales force, as well as through distribution partners.